O	0	8	COOLHAIR
O	8	9	:
O	10	11	a
O	12	23	prospective
O	24	34	randomized
O	35	40	trial
O	41	43	to
O	44	55	investigate
O	56	59	the
O	60	68	efficacy
O	69	72	and
O	73	85	tolerability
O	86	88	of
B-intervention	89	94	scalp
I-intervention	95	102	cooling
O	103	105	in
O	106	114	patients
O	115	125	undergoing
O	126	127	(
O	127	130	neo
O	130	131	)
O	131	139	adjuvant
O	140	152	chemotherapy
O	153	156	for
O	157	162	early
O	163	169	breast
O	170	176	cancer
O	176	177	.

B-condition	178	190	Chemotherapy
I-condition	190	191	-
I-condition	191	198	induced
I-condition	199	207	alopecia
I-condition	208	209	(
I-condition	209	212	CIA
I-condition	212	213	)
O	214	216	is
O	217	218	a
O	219	230	distressing
O	231	235	side
O	236	242	effect
O	243	246	for
O	247	252	women
O	253	257	with
O	258	264	breast
O	265	271	cancer
O	272	282	undergoing
O	283	295	chemotherapy
O	295	296	.

O	297	302	Scalp
O	303	310	cooling
O	311	313	is
O	314	315	a
O	316	322	method
O	323	329	aiming
O	330	332	to
O	333	340	prevent
O	341	344	CIA
O	344	345	,
O	346	349	but
O	350	353	its
O	354	362	efficacy
O	363	365	is
O	366	369	not
O	370	374	well
O	375	382	defined
O	382	383	.

O	384	394	Randomized
O	395	401	trials
O	402	407	until
O	408	416	recently
O	417	420	and
O	421	423	at
O	424	427	the
O	428	432	time
O	433	437	this
O	438	443	trial
O	444	447	was
O	448	456	designed
O	457	461	have
O	462	466	been
O	467	474	lacking
O	474	475	.

B-eligibility	476	484	Patients
I-eligibility	485	495	undergoing
I-eligibility	496	497	(
I-eligibility	497	500	neo
I-eligibility	500	501	)
I-eligibility	501	509	adjuvant
I-eligibility	510	522	chemotherapy
I-eligibility	523	526	for
I-eligibility	527	532	early
I-eligibility	533	539	breast
I-eligibility	540	546	cancer
I-eligibility	547	548	(
I-eligibility	548	551	EBC
I-eligibility	551	552	)
O	553	557	were
O	558	568	randomized
O	569	571	to
O	572	577	scalp
O	578	585	cooling
O	586	587	(
O	587	590	CAP
O	590	591	)
O	592	594	or
B-control	595	606	observation
I-control	607	608	(
I-control	608	613	NoCAP
I-control	613	614	)
O	614	615	.

O	616	619	All
O	620	628	patients
O	629	637	received
O	638	640	18
O	640	641	-
O	641	643	24
O	644	649	weeks
O	650	652	of
O	653	666	anthracycline
O	666	667	-
O	668	671	and
O	671	672	/
O	672	674	or
O	675	681	taxane
O	681	682	-
O	682	687	based
O	688	700	chemotherapy
O	700	701	.

O	702	705	The
O	706	713	primary
O	714	722	endpoint
O	723	726	was
B-outcome-Measure	727	734	patient
I-outcome-Measure	734	735	-
I-outcome-Measure	735	743	reported
I-outcome-Measure	744	748	rate
I-outcome-Measure	749	751	of
I-outcome-Measure	752	760	alopecia
O	761	770	according
O	771	773	to
O	774	775	a
O	776	784	modified
O	785	792	version
O	793	795	of
O	796	799	the
O	800	804	Dean
O	805	810	Scale
O	810	811	.

O	812	816	Hair
O	817	829	preservation
O	830	833	was
O	834	841	defined
O	842	844	as
O	845	849	hair
O	850	854	loss
O	855	856	≤
O	857	862	grade
O	863	864	2
O	865	866	(
O	866	867	≤
O	868	870	50
O	870	871	%
O	871	872	)
O	872	873	.

O	874	883	Secondary
O	884	893	endpoints
O	894	898	were
B-outcome-Measure	899	903	rate
I-outcome-Measure	904	906	of
I-outcome-Measure	907	915	alopecia
I-outcome-Measure	916	926	determined
I-outcome-Measure	927	929	by
I-outcome-Measure	930	937	medical
I-outcome-Measure	938	943	staff
O	943	944	,
B-outcome-Measure	945	949	rate
I-outcome-Measure	950	952	of
I-outcome-Measure	953	956	wig
I-outcome-Measure	956	957	/
I-outcome-Measure	957	962	scarf
I-outcome-Measure	963	966	use
O	966	967	,
B-outcome-Measure	968	980	tolerability
O	981	983	as
O	984	988	well
O	989	991	as
B-outcome-Measure	992	999	quality
I-outcome-Measure	1000	1002	of
I-outcome-Measure	1003	1007	life
I-outcome-Measure	1008	1009	(
I-outcome-Measure	1009	1012	QoL
I-outcome-Measure	1012	1013	)
O	1013	1014	.

B-total-participants	1015	1022	Seventy
I-total-participants	1022	1023	-
I-total-participants	1023	1027	nine
O	1028	1036	patients
O	1037	1041	were
O	1042	1052	randomized
O	1052	1053	.

B-outcome	1054	1058	Hair
I-outcome	1059	1071	preservation
O	1072	1075	was
O	1076	1084	observed
O	1085	1087	in
B-iv-bin-percent	1088	1090	39
I-iv-bin-percent	1090	1091	.
I-iv-bin-percent	1091	1092	3
I-iv-bin-percent	1092	1093	%
O	1094	1096	of
O	1097	1105	patients
O	1106	1108	in
O	1109	1112	the
O	1113	1116	CAP
O	1117	1120	arm
O	1121	1127	versus
B-cv-bin-percent	1128	1129	0
I-cv-bin-percent	1129	1130	%
O	1131	1133	in
O	1134	1137	the
O	1138	1143	NoCAP
O	1144	1147	arm
O	1148	1149	(
O	1149	1150	p
O	1151	1152	<
O	1153	1154	0
O	1154	1155	.
O	1155	1158	001
O	1158	1159	)
O	1159	1160	.

B-outcome	1161	1164	Wig
I-outcome	1164	1165	/
I-outcome	1165	1170	scarf
I-outcome	1171	1174	use
O	1175	1178	was
O	1179	1192	significantly
O	1193	1197	less
O	1198	1206	frequent
O	1207	1209	in
O	1210	1213	the
O	1214	1217	CAP
O	1218	1223	group
O	1224	1225	(
B-iv-bin-percent	1225	1227	40
I-iv-bin-percent	1227	1228	.
I-iv-bin-percent	1228	1229	7
I-iv-bin-percent	1229	1230	%
O	1231	1233	vs
B-cv-bin-percent	1234	1236	95
I-cv-bin-percent	1236	1237	.
I-cv-bin-percent	1237	1238	5
I-cv-bin-percent	1238	1239	%
O	1240	1247	outside
O	1248	1252	home
O	1253	1259	before
O	1260	1265	cycle
O	1266	1267	3
O	1267	1268	,
O	1269	1270	p
O	1271	1272	<
O	1273	1274	0
O	1274	1275	.
O	1275	1278	001
O	1278	1279	)
O	1279	1280	.

O	1281	1284	The
B-outcome	1285	1289	drop
I-outcome	1289	1290	-
I-outcome	1290	1293	out
I-outcome	1294	1298	rate
O	1299	1302	was
B-iv-bin-percent	1303	1305	31
I-iv-bin-percent	1305	1306	.
I-iv-bin-percent	1306	1307	7
I-iv-bin-percent	1307	1308	%
O	1309	1312	and
B-cv-bin-percent	1313	1315	34
I-cv-bin-percent	1315	1316	.
I-cv-bin-percent	1316	1317	2
I-cv-bin-percent	1317	1318	%
O	1319	1321	in
O	1322	1325	the
O	1326	1329	CAP
O	1330	1333	and
O	1334	1339	NoCAP
O	1340	1343	arm
O	1343	1344	,
O	1345	1357	respectively
O	1357	1358	.

O	1359	1363	Main
O	1364	1371	reasons
O	1372	1375	for
O	1376	1380	drop
O	1380	1381	-
O	1381	1384	out
O	1385	1389	were
B-outcome	1390	1394	hair
I-outcome	1395	1399	loss
I-outcome	1399	1400	,
I-outcome	1401	1408	adverse
I-outcome	1409	1415	events
O	1416	1417	(
O	1417	1420	CAP
O	1420	1421	)
O	1421	1422	,
O	1423	1426	and
O	1427	1440	randomization
O	1441	1445	into
O	1446	1453	control
O	1454	1457	arm
O	1457	1458	.

O	1459	1461	We
O	1462	1470	observed
O	1471	1473	no
O	1474	1485	differences
O	1486	1488	in
B-outcome	1489	1497	efficacy
O	1498	1505	between
O	1506	1519	anthracycline
O	1519	1520	-
O	1520	1525	based
O	1526	1529	and
O	1530	1533	non
O	1533	1534	-
O	1534	1547	anthracycline
O	1547	1548	-
O	1548	1553	based
O	1554	1562	regimens
O	1562	1563	.

B-outcome	1564	1567	QoL
O	1568	1571	did
O	1572	1575	not
O	1576	1582	differ
O	1583	1590	between
O	1591	1594	the
O	1595	1600	study
O	1601	1605	arms
O	1605	1606	.

O	1607	1611	This
O	1612	1617	trial
O	1618	1622	adds
O	1623	1625	to
O	1626	1629	the
O	1630	1638	evidence
O	1639	1643	that
O	1644	1649	scalp
O	1650	1657	cooling
O	1658	1669	effectively
O	1670	1678	prevents
O	1679	1682	CIA
O	1683	1685	in
O	1686	1687	a
O	1688	1698	meaningful
O	1699	1705	number
O	1706	1708	of
O	1709	1717	patients
O	1717	1718	.

O	1719	1723	This
O	1724	1730	option
O	1731	1737	should
O	1738	1740	be
O	1741	1745	made
O	1746	1755	available
O	1756	1759	for
O	1760	1768	patients
O	1769	1779	undergoing
O	1780	1781	(
O	1781	1784	neo
O	1784	1785	)
O	1785	1793	adjuvant
O	1794	1806	chemotherapy
O	1807	1810	for
O	1811	1814	EBC
O	1814	1815	.
